费城染色体样急性淋巴细胞白血病的研究进展  

Research progress of Philadelphia chromosome-like acute lymphoblastic leukemia

作　　者：许国发 陈苏宁[1] 刘立民[1] 潘金兰[1] 朱明清[1] 吴德沛[1] 仇惠英[1] XU Guofa;CHEN Suning;LIU Limin

机构地区：[1]苏州大学第一附属医院血液科江苏省血液研究所国家血液系统疾病临床医学研究中心,国家卫生健康委员会血栓与止血重点实验室,江苏苏州215006 [2]重庆市涪陵中心医院血液科,重庆400800

出　　处：《临床血液学杂志》2021年第7期517-522,526,共7页Journal of Clinical Hematology

基　　金：江苏省科教强卫工程-临床医学中心(No:YXZXA2016002)。

摘　　要：费城染色体样急性淋巴细胞白血病(Philadelphia chromosome-like acute lymphoblastic leukemia,Ph-like ALL),又称Ph样急性淋巴细胞白血病或BCR-ABL1样急性淋巴细胞白血病,其基因表达谱与费城染色体阳性急性淋巴细胞白血病(Ph+ALL)相似,但缺乏BCR-ABL1融合基因易位[1-2]。Philadelphia chromosome-like acute lymphoblastic leukemia(Ph-like ALL) also be known as BCR/ABL1-like acute lymphoblastic leukaemia. Gene expression profiling is heterogeneous in Ph-like ALL. Ph-like ALL is generally considered to be associated with a series of molecular abnormalities associated with the activation of cytokine receptors and kinase signaling pathways, and is often associated with the development of lymphoid transcription factor gene abnormalities. Early diagnosis is critical because targeted drug therapy can significantly improve the prognosis of patients with ph-like ALL. This paper intends to review the clinical features, gene profiles, diagnostic patterns and current treatment strategies of Ph-like ALL for the purpose of early identification of patients and corresponding targeted therapy or clinical trials.

关 键 词：费城染色体样 急性B淋巴细胞白血病 酪氨酸激酶抑制剂 基因 

分 类 号：R733.71[医药卫生—肿瘤]